Total Payments
$549,698
2024 Payments
$50,333
Companies
20
Transactions
528
Medicare Patients
757
Medicare Billing
$132,656
Payment Breakdown by Category
Other$379,654 (69.1%)
Travel$78,242 (14.2%)
Consulting$76,803 (14.0%)
Food & Beverage$13,834 (2.5%)
Research$1,128 (0.2%)
Gifts$30.00 (0.0%)
Education$7.08 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $379,654 | 139 | 69.1% |
| Travel and Lodging | $78,242 | 130 | 14.2% |
| Consulting Fee | $76,803 | 22 | 14.0% |
| Food and Beverage | $13,834 | 227 | 2.5% |
| Unspecified | $1,128 | 8 | 0.2% |
| Gift | $30.00 | 1 | 0.0% |
| Education | $7.08 | 1 | 0.0% |
Payments by Type
General
$548,570
520 transactions
Research
$1,128
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $419,124 | 361 | $0 (2024) |
| Genentech USA, Inc. | $69,755 | 59 | $0 (2022) |
| United Therapeutics Corporation | $36,214 | 57 | $0 (2024) |
| Boehringer Ingelheim International GmbH | $16,774 | 9 | $0 (2023) |
| Merck Sharp & Dohme LLC | $7,005 | 15 | $0 (2024) |
| GlaxoSmithKline, LLC. | $117.18 | 1 | $0 (2019) |
| Amgen Inc. | $100.41 | 4 | $0 (2024) |
| Bard Peripheral Vascular, Inc. | $97.22 | 1 | $0 (2017) |
| Mylan Specialty L.P. | $83.79 | 4 | $0 (2024) |
| UCB, Inc. | $80.76 | 3 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $50,333 | 72 | United Therapeutics Corporation ($23,633) |
| 2023 | $4,777 | 32 | Merck Sharp & Dohme LLC ($1,681) |
| 2022 | $11,768 | 23 | United Therapeutics Corporation ($8,187) |
| 2021 | $80,438 | 53 | Boehringer Ingelheim Pharmaceuticals, Inc. ($76,105) |
| 2020 | $46,806 | 50 | Boehringer Ingelheim Pharmaceuticals, Inc. ($41,369) |
| 2019 | $125,667 | 91 | Boehringer Ingelheim Pharmaceuticals, Inc. ($97,267) |
| 2018 | $121,085 | 116 | Boehringer Ingelheim Pharmaceuticals, Inc. ($92,232) |
| 2017 | $108,823 | 91 | Boehringer Ingelheim Pharmaceuticals, Inc. ($86,283) |
All Payment Transactions
528 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | United Therapeutics Corporation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $580.00 | General |
| 12/17/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $18.22 | General |
| Category: Inflammation | ||||||
| 12/11/2024 | Mylan Specialty L.P. | TOBI PODHALER (Drug) | Food and Beverage | In-kind items and services | $24.73 | General |
| Category: Aminoglycosides | ||||||
| 11/11/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $28.82 | General |
| Category: Immunology | ||||||
| 11/06/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,350.00 | General |
| 11/06/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $18.63 | General |
| Category: Respiratory | ||||||
| 11/05/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $24.29 | General |
| Category: Inflammation | ||||||
| 10/28/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $23.15 | General |
| Category: Immunology | ||||||
| 10/22/2024 | United Therapeutics Corporation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,400.00 | General |
| 10/22/2024 | United Therapeutics Corporation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| 10/22/2024 | United Therapeutics Corporation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,700.00 | General |
| 10/22/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $18.02 | General |
| Category: Immunology | ||||||
| 10/19/2024 | United Therapeutics Corporation | — | Travel and Lodging | In-kind items and services | $227.86 | General |
| 10/17/2024 | United Therapeutics Corporation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,840.00 | General |
| 10/17/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,056.10 | General |
| Category: RESPIRATORY | ||||||
| 10/17/2024 | United Therapeutics Corporation | — | Food and Beverage | In-kind items and services | $104.70 | General |
| 10/15/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,380.00 | General |
| 10/15/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,380.00 | General |
| Category: RESPIRATORY | ||||||
| 10/11/2024 | United Therapeutics Corporation | — | Travel and Lodging | In-kind items and services | $191.77 | General |
| 10/10/2024 | United Therapeutics Corporation | — | Food and Beverage | In-kind items and services | $100.22 | General |
| 10/10/2024 | United Therapeutics Corporation | — | Food and Beverage | In-kind items and services | $18.79 | General |
| 10/02/2024 | Merck Sharp & Dohme LLC | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $21.29 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/30/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $24.55 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/25/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $119.12 | General |
| 09/24/2024 | United Therapeutics Corporation | — | Travel and Lodging | In-kind items and services | $15.94 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | United Therapeutics Corporation | $1,128 | 8 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 112 | 181 | $65,633 | $16,897 |
| 2022 | 5 | 142 | 214 | $66,146 | $17,752 |
| 2021 | 6 | 228 | 394 | $147,149 | $41,964 |
| 2020 | 6 | 275 | 510 | $176,863 | $56,044 |
Total Patients
757
Total Services
1,299
Medicare Billing
$132,656
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 56 | 112 | $31,106 | $7,501 | 24.1% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 15 | 27 | $16,686 | $4,627 | 27.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 30 | 30 | $15,585 | $4,134 | 26.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 11 | 12 | $2,256 | $634.92 | 28.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 72 | 136 | $37,784 | $10,106 | 26.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 27 | 27 | $14,004 | $3,523 | 25.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 15 | 15 | $6,135 | $1,784 | 29.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 12 | 15 | $4,275 | $1,248 | 29.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 16 | 21 | $3,948 | $1,092 | 27.7% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 32 | 83 | $50,594 | $15,146 | 29.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 78 | 148 | $40,784 | $10,859 | 26.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 44 | 77 | $21,561 | $6,350 | 29.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 26 | 26 | $14,232 | $4,039 | 28.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 27 | 27 | $13,906 | $3,996 | 28.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 21 | 33 | $6,072 | $1,573 | 25.9% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 41 | 118 | $67,968 | $21,764 | 32.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 67 | 163 | $43,358 | $13,860 | 32.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 49 | 52 | $26,988 | $8,686 | 32.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 63 | 106 | $21,344 | $6,330 | 29.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 26 | 26 | $11,310 | $3,536 | 31.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 29 | 45 | $5,895 | $1,868 | 31.7% |
About Dr. Joseph Lasky, MD
Dr. Joseph Lasky, MD is a Pulmonary Disease healthcare provider based in New Orleans, Louisiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1598856577.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joseph Lasky, MD has received a total of $549,698 in payments from pharmaceutical and medical device companies, with $50,333 received in 2024. These payments were reported across 528 transactions from 20 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($379,654).
As a Medicare-enrolled provider, Lasky has provided services to 757 Medicare beneficiaries, totaling 1,299 services with total Medicare billing of $132,656. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location New Orleans, LA
- Active Since 09/27/2006
- Last Updated 07/09/2007
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1598856577
Products in Payments
- OFEV (Drug) $324,027
- Esbriet (Biological) $69,114
- TYVASO (Drug) $10,933
- Xolair (Biological) $210.78
- DUPIXENT (Biological) $136.35
- NUCALA (Biological) $117.18
- TAVNEOS (Drug) $100.41
- BPV-PowerPort (Device) $97.22
- Cimzia (Drug) $80.76
- XARELTO (Drug) $51.39
- TOBI PODHALER (Drug) $48.37
- WINREVAIR (Biological) $37.47
- YUPELRI (Drug) $35.42
- UPTRAVI (Drug) $32.14
- CHARTIS CATHETER (Device) $26.68
- ZERBAXA (Drug) $21.29
- Prolastin-C Liquid (Biological) $19.18
- Arikayce (Drug) $18.63
- TREMFYA (Drug) $18.02
- (AK6) Vest Therapy (Device) $13.86
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in New Orleans
Juzar Ali, Md.,Frcp., Fccp(C), MD.,FRCP., FCCP(C)
Pulmonary Disease — Payments: $233,193
Pulmonary Disease $233,193
Dr. Ramsy Abdelghani, M.d, M.D
Pulmonary Disease — Payments: $222,746
Pulmonary Disease $222,746
Dr. William Emory, Md, MD
Pulmonary Disease — Payments: $35,923
Pulmonary Disease $35,923
Dr. Nereida Parada, Md, MD
Pulmonary Disease — Payments: $17,027
Pulmonary Disease $17,027
Dr. Ross Klingsberg, M.d, M.D
Pulmonary Disease — Payments: $11,314
Pulmonary Disease $11,314
Dr. Steve Nelson, Md, MD
Pulmonary Disease — Payments: $8,881
Pulmonary Disease $8,881